Overview of Core Asset
HTD1801 represents a new molecular entity that offers the possibility of combination therapy for chronic metabolic and liver diseases in a single treatment.
This lead compound, an investigational drug currently under evaluation in clinical studies, is a potential first-in-class orally administered anti-inflammatory metabolic modulator, providing a dual mechanism of action with the potential to treat the core aspects of chronic metabolic diseases.
Our priority in the clinic is advancing our lead candidate HTD1801 in chronic metabolic diseases driven by insulin resistance and chronic inflammation.
| Therapeutic Area | Planning | Phase 1 | Phase 2 | Phase 3 | Status |
|---|---|---|---|---|---|
T2DM | Phase 3 (Symphony 1) | NDA pending | |||
| Phase 3 (Symphony 1) Read Less | |||||
T2DM | Phase 3 (Symphony 2) | NDA pending | |||
| Phase 3 (Symphony 2) Read Less | |||||
T2DM | Phase 3 (Harmony) | Results 2H2025 | |||
| Phase 3 (Harmony) Read Less | |||||
MASH | Phase 2b (Centricity) | Results 2025 | |||
| Phase 2b (Centricity) Read Less | |||||
Obesity | Monotherapy or add-on to GLP-1 RA | ||||
| Monotherapy or add-on to GLP-1 RA Read Less | |||||
PSC | Phase 3 ready | ||||
Read Less | |||||
SHTG | Phase 2 ready | ||||
Read Less | |||||
| Therapeutic Area | Status | Phase |
|---|---|---|
T2DM |
NDA pending | Phase 3 Phase 3 (Symphony 1) |
| Phase 3 (Symphony 1) Read Less | ||
T2DM |
NDA pending | Phase 3 Phase 3 (Symphony 2) |
| Phase 3 (Symphony 2) Read Less | ||
T2DM |
Results 2H2025 | Phase 3 Phase 3 (Harmony) |
| Phase 3 (Harmony) Read Less | ||
MASH |
Results 2025 | Phase 2 Phase 2b (Centricity) |
| Phase 2b (Centricity) Read Less | ||
Obesity |
Planning Monotherapy or add-on to GLP-1 RA | |
| Monotherapy or add-on to GLP-1 RA Read Less | ||
PSC |
Phase 3 ready | Phase 2 |
Read Less | ||
SHTG |
Phase 2 ready | Phase 1 |
Read Less | ||